Anti-CGRP Antibody Timing for Rapid Headache Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for migraine and medication overuse headache are inadequate in providing rapid and effective relief, particularly for chronic migraine and headaches resulting from overuse of various medications.

Innovation Solution

Administration of anti-CGRP antibodies or fragments, such as Ab6, within 1-6 hours of headache onset, in dosages of 100-300 mg intravenously, to target and reduce CGRP activity, thereby alleviating migraine and medication overuse headaches.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If conventional migraine treatments are used, then headache relief is provided, but the relief is not rapid and effective enough for chronic migraine and medication overuse headache

Engineering Contradiction:

Improvespeed of headache reliefVSAvoideffectiveness of headache relief

Core Design Contradiction:

SpeedVSReliability

Solution Approach 1:

The patent changes the pharmacological parameter by using anti-CGRP antibodies instead of conventional migraine treatments. CGRP (calcitonin gene-related peptide) is a neuropeptide that plays a key role in migraine pathophysiology, and blocking it with antibodies provides both rapid and effective relief, resolving the contradiction between speed and reliability of headache relief.

Inventive Principle:

Principle #35Parameter changes

2Speed

If anti-CGRP antibodies are administered within 1-6 hours of headache onset, then rapid and effective relief is achieved, but the treatment window is limited

Engineering Contradiction:

Improvespeed of headache reliefVSAvoidtime window for treatment

Core Design Contradiction:

SpeedVSLoss of time

Solution Approach 1:

The patent establishes that anti-CGRP antibody administration is most effective when given within 1-6 hours of headache onset, identifying this as the optimal treatment window. This preliminary action principle highlights the importance of timely intervention to achieve rapid and effective relief, though the limited time window represents a constraint rather than a contradiction to be resolved.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Significant reduction in headache frequency and severity, with up to 100% reduction in migraine days within a month or 12 weeks, and sustained inhibition of vasodilation effects for months post-treatment.

Implementation Method 1

administering to a patient in need an effective amount of at least one anti-CGRP antibody or antibody fragment or an anti-CGRP-R antibody or antibody fragment

Methodology Applied

Scientific EffectAntibody binding:

Implementation Method 2

sustained inhibition of vasodilation effects for months post-treatment

Methodology Applied

Scientific EffectVasodilation inhibition:

Data Source

PatentUS20250368727A1Acute treatment and rapid treatment of headache using Anti-CGRP antibodies

Publication Date: 2025.12.04 H LUNDBECK AS

AI summary

Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.